LSLuis Eduardo Santos

Luis Eduardo Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luis Eduardo Santos has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating blood biomarkers after traumatic brain injury: A subanalysis of the biperiden phase III randomized, double‐blind clinical trial ( NCT01048138 )

    by Michele Longoni Calió, Maira Licia Foresti, Luis Eduardo Santos, Amanda Cristina Mosini, Clivandir Severino Silva, Clara Pompeu, Juliana Willers, Thyago Leal Calvo, Almir Ferreira de Andrade, Saul Almeida da Silva, et al.

    Objective: Traumatic brain injury (TBI) is a leading cause of acquired epilepsy, death, and long‐term disability, yet reliable biomarkers to predict chronic sequelae such as post‐traumatic epilepsy (PTE) remain limited. We evaluated the associations between circulating blood biomarkers of neuronal, glial, and synaptic injury and the subsequent development of PTE. Methods: This prespecified subanalysis was conducted within a randomized phase III clinical trial of biperiden in adults with acute TBI. Participants were randomly assigned to receive intravenous biperiden (4 mg every 6 h for 10 days) or placebo. Serum samples collected during the acute (1–15 days) or chronic (90–270 days) post‐injury periods were analyzed for total tau (t‐Tau), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), ubiquitin C‐terminal hydrolase L1 (UCHL1), and synaptosomal‐associated protein 25 (SNAP25) using an ultrasensitive single‐molecule array (SiMoA) platform. Exploratory multivariable analyses were performed to assess associations between biomarker concentrations and PTE. Results: A total of 123 patients were enrolled. Blood samples were obtained from 58 participants (60 serum samples) for biomarker analysis, with most participants contributing a single sample and only two participants providing paired samples collected at different post‐injury time points. The median age was 42 years and 48 participants (82.8%) were men. Only six patients (10.3%) developed PTE during follow‐up, four in the biperiden group and two in the placebo group. NfL and GFAP concentrations varied according to injury severity and sampling period. Compared with patients who did not develop PTE, those who later developed epilepsy showed descriptively lower NfL and SNAP25 and higher t‐Tau, GFAP, and UCHL1 concentrations. SNAP25 was detected in serum for the first time; however, concentrations were frequently below the assay's lower limit of quantification, limiting interpretation of this biomarker and no association with epilepsy development was observed. Significance: Circulating biomarkers reflecting axonal, glial, and synaptic injury provide a descriptive characterization of biological processes following TBI. Given the limited number of PTE events, these analyses are exploratory and hypothesis generating. Further studies are needed to evaluate whether blood‐based biomarkers can reliably identify individuals at risk of post‐traumatic epileptogenesis.

  • Open Access

    Fibronectin type III domain-containing protein 5/irisin in extracellular vesicles is reduced in older individuals

    by Tai R Hunter, Natalia M Lyra E Silva, Guilherme B de Freitas, Tayna Rody, Luis E Santos, Jieming Zhang, Alexis Bullock, Maria Carmela Tartaglia, Sheela Abraham, Chiara Nicolini, et al.

    The progressive accumulation of physiological stress as we age, known as allostatic load, is linked to an increased risk of dementia. Fostering brain resilience through physical exercise can counteract allostatic load and improve adaptation to age-related brain alterations. Fibronectin type III domain-containing protein 5 (FNDC5)/irisin is a neuroprotective exercise-linked hormone found in extracellular vesicles (EV-FNDC5/irisin). Here, we sought to analyse EV-FNDC5/irisin in ageing as a promising biomarker of brain resilience. We measured exercise-associated factors, including EV-FNDC5/irisin, brain-derived neurotrophic factor (BDNF), and cathepsin B in the serum of 31 young (18–28 years) and 19 older subjects (65–79 years). Levels of FNDC5/irisin in serum-derived EVs are markedly reduced in older subjects compared to young (P = 0.004). We report a reduction in nanoparticles isolated from the serum of older participants (P = 0.009). While EV-FNDC5/irisin positively correlates with BDNF in young subjects (Spearman r = 0.40, P = 0.038), this correlation is absent in elderly subjects (Spearman r = −0.25, P = 0.34). This study provides initial evidence that EV-FNDC5/irisin is reduced in older individuals and loses correlation with BDNF. Our identification of peripheral, exercise-linked factors associated with age may inform biomarker discovery and interventions to promote brain resilience.

  • Open Access

    Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

    by Luis E. Santos, Paulo E. Mattos, Thaís Lopes Pinheiro, Ananssa Silva, Claudia Drummond, Felipe K. Sudo, Fernanda G. Q. Barros‐Aragão, Bart Vanderborght, Carlos O Brandão, Sergio T. Ferreira, et al.

    Background: Dementia is a growing concern throughout the developing world and is severely underdiagnosed among the Brazilian population. Despite remarkable progress in the biomarker field in recent years, local testing and validation of plasma biomarkers of AD and dementia is still lacking in Brazil and Latin America. Methods: In this longitudinal cohort study of 145 participants, the diagnostic performance of plasma biomarkers was assessed based on clinical diagnosis and CSF biomarker positivity. Follow‐up data of up to 4.7 years were used to determine biomarker performance in predicting diagnostic conversions. The study was conducted at the Memory Clinic at the D’Or Institute for Research and Education (IDOR) in Rio de Janeiro. Participants were volunteers referred to the service. All were native Brazilians, had Portuguese as their first language and 60+ years of age. They were clinically diagnosed and underwent psychiatric and laboratory assessments. Diagnoses outside the scope of the study were excluded. CSF biomarker data was available for 36% of the sample. Participants were categorized as cognitively unimpaired (CU; n = 49) or cognitively impaired (CI; n = 96), with CI participants further classified as aMCI, Alzheimer's disease (AD), Lewy body dementia, or vascular dementia. Plasma Tau, Aβ 40 , Aβ 42 , NfL, GFAP, pTau231, pTau181 and pTau217 were measured at initial and follow‐up visits using a SIMOA HD‐X instrument. To assess the diagnostic performance of each biomarker, receiver operating characteristic (ROC) curve analysis was performed. Results: The pTau217/Aβ 42 ratio was the top‐performing biomarker for discrimination between CSF‐biomarker‐negative and CSF‐biomarker‐positive subjects (AUC=0.98, 95% CI: [0.94 – 1.00]), followed by pTau217 alone (AUC=0.94, 95% CI: [0.88 – 1.00]. When discriminating participants based on their cognitive status (CU x CI), pTau217 and pTau217/Aβ 42 ratio reached identical AUCs of 0.82 (95% CI: [0.75 – 0.89]). Similar results were seen when discriminating CU from all‐cause dementia, with pTau217 and pTau217/Aβ 42 ratio tied at the highest AUCs (AUC=0.87, 95% CI: [0.80 – 0.94]). Conclusions: In this first biomarker profiling of a Brazilian dementia cohort, plasma pTau217 confirmed its potential as a clinically useful diagnostic tool. This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil and Latin America.

  • Open Access

    Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

    by Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, et al.

    Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.


  • Open Access

    Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

    by Luis E Santos, Paulo Mattos, Thaís Pinheiro, Ananssa Silva, Claudia Drummond, Felipe K. Sudo, Fernanda Barros‐Aragão, Bart Vanderborght, Carlos O Brandão, Sergio T Ferreira, et al.

    Background: Dementia is a growing concern throughout the developing world and is severely underdiagnosed among the Brazilian population. Despite remarkable progress in the biomarker field in recent years, local testing and validation of plasma biomarkers of AD and dementia is still lacking in Brazil and Latin America.Method: In this longitudinal cohort study of 145 participants, the diagnostic performance of plasma biomarkers was assessed based on clinical diagnosis and CSF biomarker positivity. Follow‐up data of up to 4.7 years were used to determine biomarker performance in predicting diagnostic conversions. The study was conducted at the Memory Clinic at the D’Or Institute for Research and Education (IDOR) in Rio de Janeiro. Participants were volunteers referred to the service. All were native Brazilians, had Portuguese as their first language and 60+ years of age. They were diagnosed (DSM‐5 criteria) and underwent extensive psychiatric and laboratory assessments. Diagnoses outside the scope of the study were excluded. CSF biomarker data was available for 34% of the sample. Participants were categorized as cognitively normal controls (n = 49), amnestic mild cognitive impairment (aMCI; n = 29), Alzheimer’s disease (AD; n = 37), Lewy body dementia (n = 23), or vascular dementia (n = 7). Plasma samples collected at initial and follow‐up visits were tested for relevant biomarkers.Result: Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231 and pTau181 were measured on the SIMOA HD‐X platform. Results were evaluated against clinical diagnosis and CSF biomarker status. Plasma NfL and GFAP could discriminate between all‐cause dementia and controls with ROC AUCs of 0.79 (95% CI: [0.70–0.87]) and 0.74 [0.65–0.83], respectively. Plasma pTau181 had good diagnostic performance discriminating clinical AD (AUC = 0.89 [0.82–0.96]), CSF‐biomarker+ aMCI/AD (AUC = 0.90 [0.82–0.98]), or CSF‐biomarker‐confirmed AD (AUC = 0.95 [0.89–1.00]) from controls.Conclusion: In this first description of the plasma biomarker profile of a Brazilian dementia cohort, plasma pTau181 confirmed its potential as a clinically useful diagnostic tool. This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil and Latin America.

  • Alzheimer’s disease biomarkers and their current use in clinical research and practice

    by Tai R. Hunter, Luis E. Santos, Fernanda Tovar-Moll, Fernanda G. De Felice

    While blood-based tests are readily available for various conditions, including cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer’s disease (AD) and other neurodegenerative diseases lack an early blood-based screening test that can be used in primary care. Major efforts have been made towards the investigation of approaches that may lead to minimally invasive, cost-effective, and reliable tests capable of measuring brain pathological status. Here, we review past and current technologies developed to investigate biomarkers of AD, including novel blood-based approaches and the more established cerebrospinal fluid and neuroimaging biomarkers of disease. The utility of blood as a source of AD-related biomarkers in both clinical practice and interventional trials is discussed, supported by a comprehensive list of clinical trials for AD drugs and interventions that list biomarkers as primary or secondary endpoints. We highlight that identifying individuals in early preclinical AD using blood-based biomarkers will improve clinical trials and the optimization of therapeutic treatments as they become available. Lastly, we discuss challenges that remain in the field and address new approaches being developed, such as the examination of cargo packaged within extracellular vesicles of neuronal origin isolated from peripheral blood.


  • Open Access

    Prospects and challenges in using neuronal extracellular vesicles in biomarker research

    by Debora A. S. Rocha, Luis E. Santos, Pedro B. Da Fonseca, Fernanda G. De Felice

    Extracellular vesicles (EVs) hold promise as a source of disease biomarkers. The diverse molecular cargo of EVs can potentially indicate the status of their tissue of origin, even against the complex background of whole plasma. The main tools currently available for assessing biomarkers of brain health include brain imaging and analysis of the cerebrospinal fluid of patients. Given the costs and difficulties associated with these methods, isolation of EVs of neuronal origin (NEVs) from the blood is an attractive approach to identify brain‐specific biomarkers. This perspective describes current key challenges in EV‐ and NEV‐based biomarker research. These include the relative low abundance of EVs, the lack of validated isolation methods, and the difficult search for an adequate target for immunocapturing NEVs. We discuss that these challenges must be addressed before NEVs can fulfill their potential for biomarker research.Highlights: NEVs are promising sources of biomarkers for brain disorders. Immunocapturing NEVs from complex biofluids presents several challenges. The choice of surface target for capture will determine NEV yield. Contamination by non‐EV sources is relevant for biomarkers at low concentrations.


  • Open Access

    Brain FNDC5/Irisin Expression in Patients and Mouse Models of Major Depression

    by Ricardo Lima-Filho, Juliana S. Fortuna, Danielle Cozachenco, Alinny R. Isaac, Natalia Lyra e Silva, Alice Saldanha, Luis E. Santos, Sergio T. Ferreira, Mychael V. Lourenco, Fernanda G. De Felice

    Major depressive disorder (MDD) is a major cause of disability in adults. MDD is both a comorbidity and a risk factor for Alzheimer’s disease (AD), and regular physical exercise has been associated with reduced incidence and severity of MDD and AD. Irisin is an exercise-induced myokine derived from proteolytic processing of fibronectin type III domain-containing protein 5 (FNDC5). FNDC5/irisin is reduced in the brains of AD patients and mouse models. However, whether brain FNDC5/irisin expression is altered in depression remains elusive. Here, we investigate changes infndc5expression in postmortem brain tissue from MDD individuals and mouse models of depression. We found decreasedfndc5expression in the MDD prefrontal cortex, both with and without psychotic traits. We further demonstrate that the induction of depressive-like behavior in male mice by lipopolysaccharide decreasedfndc5expression in the frontal cortex, but not in the hippocampus. Conversely, chronic corticosterone administration increasedfndc5expression in the frontal cortex, but not in the hippocampus. Social isolation in mice did not result in alteredfndc5expression in either frontal cortex or hippocampus. Finally, fluoxetine, but not other antidepressants, increasedfndc5gene expression in the mouse frontal cortex. Results indicate a region-specific modulation offndc5in depressive-like behavior and by antidepressant in mice. Our finding of decreased prefrontal cortexfndc5expression in MDD individuals differs from results in mice, highlighting the importance of carefully interpreting observations in mice. The reduction infndc5mRNA suggests that decreased central FNDC5/irisin could comprise a shared pathologic mechanism between MDD and AD.


  • Rapid size-exclusion high performance liquid chromatography method for the quality control of amyloid-β oligomers

    by Igor Camargo Fontana, Pâmela Cristina Lukasewicz Ferreira, Diogo Miron, Luis Eduardo Santos, Sergio T. Ferreira, Diogo Onofre Souza, Grace Gosmann, Eduardo R. Zimmer, Aline Rigon Zimmer


  • Open Access

    Diet-Derived Fatty Acids, Brain Inflammation, and Mental Health

    by Helen M. Melo, Luís Eduardo Santos, Sergio T. Ferreira

    Western societies experienced drastic changes in eating habits during the past century. The modern nutritional profile, typically rich in saturated fats and refined sugars, is recognized as a major contributing factor, along with reduced physical activity, to the current epidemics of metabolic disorders, notably obesity and diabetes. Alongside these conditions, recent years have witnessed a gradual and significant increase in prevalence of brain diseases, particularly mood disorders. While substantial clinical/epidemiological evidence supports a correlation between metabolic and neuropsychiatric disorders, the mechanisms of pathogenesis in the latter are often multifactorial and causal links have been hard to establish. Neuroinflammation stands out as a hallmark feature of brain disorders that may be linked to peripheral metabolic dyshomeostasis caused by an unhealthy diet. Dietary fatty acids are of particular interest, as they may play a dual role, both as a component of high-calorie obesogenic diets and as signaling molecules involved in inflammatory responses. Here, we review current literature connecting diet-related nutritional imbalance and neuropsychiatric disorders, focusing on the role of dietary fatty acids as signaling molecules directly relevant to inflammatory processes and to neuronal function.